Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
100 participants
INTERVENTIONAL
2011-01-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223
Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation
NCT00445263
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
NCT01936896
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
NCT07276282
Occluded Artery Trial (OAT)
NCT00004562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy patients
ALOA IgG-Elisa
measurement of IgG Level in blood
ALOA IgG-AtheroAbzyme
measurement of IgG in blood
Asymptomatic myocardial Ischemic patients
ALOA IgG-Elisa
measurement of IgG Level in blood
ALOA IgG-AtheroAbzyme
measurement of IgG in blood
Acute Coronary Syndrome Patients
ALOA IgG-Elisa
measurement of IgG Level in blood
ALOA IgG-AtheroAbzyme
measurement of IgG in blood
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALOA IgG-Elisa
measurement of IgG Level in blood
ALOA IgG-AtheroAbzyme
measurement of IgG in blood
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High Risk patients or Asymptomatic myocardial Ischemic patients
* Acute Coronary Syndrome patients
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Omicron Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omicron Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malek Mohamad
Role: PRINCIPAL_INVESTIGATOR
Bahman Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bahman Hospital
Beirut, Haret Hriek, Lebanon
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OP512011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.